IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

Core Insights - IDEAYA Biosciences has announced a research collaboration with ATTMOS to develop a physics-based computational small molecule discovery platform targeting undruggable oncology targets [1][2] - The partnership aims to integrate IDEAYA's structural biology and drug discovery capabilities with ATTMOS's computational chemistry and software development expertise [2][3] - The collaboration will utilize the Amber molecular dynamics suite for free energy simulations and aims to enhance the efficiency of drug discovery for novel oncology therapeutics [4] Company Overview - IDEAYA Biosciences focuses on precision medicine in oncology, developing targeted therapeutics based on molecular diagnostics [5] - The company is committed to identifying and validating translational biomarkers to select patient populations that will benefit from its therapies [5] ATTMOS Overview - ATTMOS was founded in early 2022 by a team of academics from Michigan State, Rutgers, and UC San Diego [6] - The company's mission is to integrate novel technologies into the drug discovery process, making them affordable and accessible [6]